Demographic characteristics, liver/hepatitis B virus test results, fibrosis and treatment of Canadians with chronic hepatitis B, by sex and age
| Variable | No. (%) of patients* (95% CI) | |||
|---|---|---|---|---|
| Men n = 5193 | Women n = 4187 | Age < 40 yr n = 2621 | Age ≥ 40 yr n = 6759 | |
| Age, yr, mean (median) | 49.9‡ (50) (49.56–50.30) | 48.0‡ (47) (47.59–48.46) | 32.7§ (33) (32.48–32.85) | 55.4§ (54) (55.19–55.7) |
| Male sex | 5193 (100.0)‡ (99.91–100.00) | –‡ | 1260 (48.1)§ (46.15–50.01) | 3933 (58.2)§ (57.00–59.37) |
| Born in Canada | 47 (0.9) (0.67–1.21) | 33 (0.8) (0.55–1.12) | 22 (0.8)§ (0.54–1.29) | 58 (0.8)§ (0.66–1.12) |
| Immigrant status missing | 3943 (75.9) (74.74–77.08) | 3120 (74.5) (73.16–75.83) | 1922 (73.3)§ (71.59–75.01) | 5141 (76.1)§ (75.02–77.07) |
| Asian | 3147 (60.6)‡ (59.25–61.93) | 2656 (63.4)‡ (61.95–64.89) | 1510 (57.6)§ (55.69–59.51) | 4293 (63.5)§ (62.35–64.66) |
| Black/African/Caribbean | 516 (9.9)‡ (9.14–10.79) | 400 (9.6)‡ (8.69–10.49) | 433 (16.5)§ (15.13–18.01) | 483 (7.1)§ (6.55–7.79) |
| White | 562 (10.8)‡ (10.00–11.71) | 352 (8.4)‡ (7.59–9.30) | 168 (6.4)§ (5.52–7.43) | 746 (11.0)§ (10.30–11.81) |
| Ethnicity missing | 834 (16.1)‡ (15.08–17.09) | 688 (16.4)‡ (15.33–17.60) | 427 (16.3)§ (14.91–17.77) | 1095 (16.2)§ (15.33–17.11) |
| HBeAg positive | 659 (12.7)‡ (11.80–13.63) | 581 (13.9)‡ (12.85–14.97) | 578 (22.0)§ (20.49–23.70) | 662 (9.8)§ (9.10–10.53) |
| HBeAg status missing | 1384 (26.6)‡ (25.46–27.88) | 1200 (28.7)‡ (27.30–30.06) | 747 (28.5)§ (26.79–30.28) | 1837 (27.2)§ (26.12–28.26) |
| HBV DNA level < 2000 IU/mL | 1235 (23.8) (22.63–24.97) | 1084 (25.9) (24.57–27.25) | 681 (26.0)§ (24.32–27.72) | 1638 (24.2)§ (23.22–25.28) |
| HBV DNA level missing | 3673 (70.7) (69.47–71.96) | 2887 (69.0) (67.52–70.35) | 1776 (67.8)§ (65.93–69.54) | 4784 (70.8)§ (69.68–71.86) |
| Alanine transaminase level, U/L, mean (median)† | 48.2‡ (31) (43.45–52.86) | 30.5‡ (22) (28.66–32.43) | 42.5 (27) (36.27–48.67) | 39.3 (27) (36.34–42.18) |
| Stage F3–4 fibrosis | 232 (4.5) (3.93–5.07) | 92 (2.2) (1.78–2.70) | 37 (1.4)§ (1.01–1.96) | 287 (4.2)§ (3.78–4.76) |
| Fibrosis data missing | 2753 (53.0) (51.64–54.38) | 2367 (56.5) (55.01–58.04) | 1601 (61.1)§ (59.18–62.95) | 3519 (52.1)§ (50.86–53.26) |
| Lamivudine prescription (at any time) | 926 (17.8)‡ (16.81–18.91) | 508 (12.1)‡ (11.17–13.17) | 217 (8.3)§ (7.27–9.42) | 1217 (18.0)§ (17.10–18.95) |
| Tenofovir disoproxil prescription (at any time) | 1087 (20.9)‡ (19.84–22.07) | 568 (13.6)‡ (12.55–14.65) | 350 (13.4)§ (12.09–14.73) | 1305 (19.3)§ (18.38–20.27) |
| Entecavir prescription (at any time) | 350 (6.7)‡ (6.08–7.46) | 198 (4.7)‡ (4.12–5.43) | 93 (3.5)§ (2.89–4.35) | 455 (6.7)§ (6.15–7.36) |
| Treatment data missing | 90 (1.7)‡ (1.40–2.14) | 49 (1.2)‡ (0.88–1.56) | 35 (1.3)§ (0.95–1.87) | 104 (1.5)§ (1.26–1.87) |
Note: CI = confidence interval, HBeAg = hepatitis B e-antigen, HBV = hepatitis B virus.
↵* Except where noted otherwise.
↵† Data missing for 3078 men, 2422 women, 1556 patients aged less than 40 years and 3944 patients aged 40 years or more.
↵‡ p < 0.05 for difference between men and women.
↵§ p < 0.05 for difference between patients aged less than 40 years and those aged 40 years or more.